FOXO4-DRI
FOXO4-p53 · Senolytic peptide
Engineered D-retro-inverso peptide that selectively induces apoptosis in senescent cells, reversing aging hallmarks in mice.
Half-Life
~4–6 hours (DRI form is more stable than L-form)
MW
N/A
Amino Acids
N/A
Evidence
Preclinical
Regulatory Status
Research compound only
In Plain English
A precision "terminator" for zombie cells — the damaged, dysfunctional senescent cells that accumulate with aging and drive chronic inflammation. It selectively triggers self-destruct in these cells while leaving healthy cells completely untouched.
Overview
FOXO4-DRI is a D-amino acid retro-inverso (DRI) form of a FOXO4 peptide segment that disrupts the FOXO4-p53 interaction in senescent cells. By blocking this survival signal, it selectively triggers apoptosis (programmed death) in harmful senescent cells without affecting healthy cells. Landmark mouse studies showed restoration of fitness, fur density, and kidney function in fast-aging mice. One of the most exciting senolytics in early research.
Common Formats
- Injectable (intraperitoneal in studies)
- Injectable (subcutaneous in self-experiments)
Storage Notes
Freeze at -20°C. Reconstituted: refrigerate and use within 7 days.
Looking for multi-compound protocols?
Browse educational protocol discussions that include FOXO4-DRI.
Related Compounds
Humanin
A mitochondria-derived peptide encoded in the 16S rRNA region with remarkable cytoprotective, anti-apoptotic, and longevity-associated properties.
SS-31
A cardiolipin-targeted mitochondria-protective peptide showing remarkable results in heart failure, AMD, and mitochondrial disease research.
MOTS-c
A mitochondrial-derived peptide that regulates metabolic homeostasis, glucose uptake, and has shown remarkable longevity effects in animal studies.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.